Julie Prosseda, MD
Family Medicine · Wilmington, DENPI 1538168208
Payments from drug & device makers
Across 420 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$540
- Amgen$529
- Astellas Pharma US Inc$405
- Novo Nordisk$383
- AstraZeneca$375
- plus $3K from 50 others
What the payments were for
- Consulting fees$250%
- Food & beverage$7,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,039 in reported general payments places this provider in the 90th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $90,717 |
| TrulicityDulaglutide | 37 | $69,025 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $50,757 |
| JardianceEmpagliflozin | 20 | $34,717 |
| EliquisApixaban | 26 | $33,315 |
| OpzeluraRuxolitinib Phosphate | 15 | $30,979 |
| XareltoRivaroxaban | 25 | $27,103 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $20,959 |
| JanuviaSitagliptin Phosphate | 11 | $18,030 |
| NucyntaTapentadol Hcl | 12 | $10,698 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $8,611 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,313 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 19 | $5,960 |
| SynthroidLevothyroxine Sodium | 90 | $5,858 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $383 | $90,71783 claims |
| Lilly USA, LLCTrulicity | $540 | $69,02537 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Shingrix | $348 | $64,64073 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $156 | $41,03033 claims |
| PfizerEliquis | $113 | $33,31526 claims |
| Johnson & JohnsonXarelto | $221 | $27,10325 claims |
| MerckJanuvia | $216 | $18,03011 claims |
| AbbVieSynthroid | $1,352 | $5,85890 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 family medicine providers in Delaware.
Other family medicine in Wilmington
- David KrasnerWilmington$110K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Glenn HamiltonWilmington$17K
- Lakan Karlo MagatWilmington$16K
- Marc GrobmanWilmington$13K
- Julio NavarroWilmington$13K
- Anna MagatWilmington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.